Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Pyxis Oncology, Inc. (PYXS) had Return on Tangible Equity of -221.56% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-25.35M |
|
-- |
|
-- |
|
$25.99M |
|
$-25.99M |
|
$0.64M |
|
$-25.35M |
|
$-25.35M |
|
$-25.35M |
|
$-25.35M |
|
$-25.35M |
|
$-25.35M |
|
$-25.99M |
|
$-25.88M |
|
63.99M |
|
63.99M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$36.73M |
|
$7.24M |
|
$18.19M |
|
$54.92M |
|
$27.47M |
|
-- |
|
$16.01M |
|
$43.48M |
|
$11.44M |
|
$11.44M |
|
$11.44M |
|
63.44M |
|
| Cash Flow Statement Financials | |
$-44.21M |
|
$37.67M |
|
$9.97M |
|
$16.89M |
|
$20.33M |
|
$3.43M |
|
$6.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-44.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-221.56% |
|
|
Return on Tangible Equity |
-221.56% |
-46.15% |
|
-221.56% |
|
$0.18 |
|
$-0.69 |
|
$-0.69 |
|